Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Patent ductus arteriosus

Paediatrics and child health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Pulmonary overcirculation or systemic steal

A large duct in a very preterm infant can worsen respiratory failure, pulmonary haemorrhage, hypotension, renal or gut perfusion and heart failure; in an older infant it may cause severe feeding and growth compromise.

Action: Stabilise airway, breathing, temperature and circulation, obtain neonatal or paediatric cardiology review and perform targeted echocardiography. Treat infection and other causes of deterioration, optimise ventilation and fluids, and decide active closure through the neonatal or congenital cardiac team; do not give ibuprofen when major contraindications such as active bleeding, severe renal impairment, necrotising enterocolitis or uncontrolled infection are present.

Synopsis

Explain why the arterial duct persists in different age groups, recognise haemodynamically important pulmonary overcirculation, and choose observation, neonatal pharmacological closure, catheter treatment or surgery safely.

  • The arterial duct connects the pulmonary artery to the descending aorta in fetal life. Oxygen exposure and falling prostaglandins normally trigger functional then anatomical closure after birth.
  • Prematurity strongly favours persistence because ductal smooth muscle is immature and illness, hypoxaemia and circulating prostaglandins oppose constriction.
  • After pulmonary resistance falls, a PDA usually carries left-to-right flow, creating pulmonary overcirculation, left-heart volume loading and diastolic runoff from systemic circulation.
  • Classic findings in a term infant or child are a continuous left infraclavicular machinery murmur, bounding pulses and wide pulse pressure; very preterm infants often have less typical signs.
  • Initial assessment combines respiratory and feeding burden, pulse and perfusion pattern, blood pressure and serial targeted neonatal or paediatric echocardiography.
  • Echocardiography confirms ductal anatomy, direction and velocity of flow, left-heart loading and systemic-flow effects and excludes a lesion that depends on ductal patency.
  • An asymptomatic tiny duct may be observed or discussed for elective closure; a persistent haemodynamically important duct needs specialist assessment for treatment.
  • For a haemodynamically significant PDA in an eligible preterm infant, a licensed ibuprofen course is 10 mg/kg IV, then 5 mg/kg at 24 and 48 hours, with renal, bleeding, gut and infection safety checks before every dose.
  • A suitable persistent PDA in an older infant or child is usually closed by a transcatheter device; surgery is used when size, weight, anatomy or failed pharmacological or catheter treatment makes that preferable.
  • Do not treat a PDA number in isolation: evidence for active closure in extremely preterm infants is context-dependent, so gestation, respiratory course, systemic effects and local neonatal policy determine timing.

Key red flags

Increasing ventilatory requirement, pulmonary haemorrhage, hypotension or poor systemic perfusion in a very preterm infant warrants urgent haemodynamic reassessment for a significant duct and other causes.

Tachypnoea, feeding diaphoresis, hepatomegaly, bounding pulses and faltering growth indicate substantial pulmonary overcirculation in an infant beyond the immediate newborn period.

A continuous murmur may be absent in a ventilated preterm baby or when pulmonary and systemic pressures are similar; haemodynamic significance cannot be graded by sound alone.

Central cyanosis or differential lower-limb cyanosis suggests pulmonary hypertension with right-to-left ductal flow or additional congenital anatomy and needs urgent specialist assessment.

Oliguria, rising creatinine, thrombocytopenia, active bleeding, suspected necrotising enterocolitis or severe infection materially changes the safety of cyclo-oxygenase inhibitor treatment.

A duct that is maintaining pulmonary or systemic flow in another congenital lesion must not be closed; confirm complete anatomy before intervention.

Investigation priorities

01
Initial cardiorespiratory and growth assessmentFirst step

Establish clinical burden across respiratory support, perfusion, feeding and growth.

Management branches

Preterm assessmentDefine haemodynamic significance

A preterm infant has a persistent duct and respiratory or systemic concerns.

  1. Integrate gestation, ventilation, oxygen, perfusion, feeds and serial echocardiographic flow effects.
  2. Treat alternative causes of deterioration and optimise ventilation, nutrition and fluid balance without provoking dehydration.
  3. Discuss conservative, pharmacological or procedural closure within the neonatal and cardiac multidisciplinary pathway.

Key medicines

Ibuprofen intravenous (Pedea 5 mg/mL)Preterm neonatal licensed course: 10 mg/kg IV for the first dose, followed by 5 mg/kg IV 24 hours later and 5 mg/kg IV a further 24 hours later; administer each dose over 15 minutes and reassess ductal closure.Exclude duct-dependent congenital disease. Do not use with life-threatening infection, active bleeding, thrombocytopenia or coagulation defect, significant renal impairment, or suspected or active necrotising enterocolitis; withhold a later dose during anuria or marked oliguria and review nephrotoxic interactions.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • Pedea injection SmPCLicensed intravenous ibuprofen indication, regimen and neonatal safety restrictions.
  • Great Ormond Street patent ductus arteriosusUK tertiary-centre explanation of PDA physiology and closure.
  • NHS congenital heart diseaseNational overview of congenital anatomy, catheter procedures and surgical treatment.
  • British Heart Foundation congenital diseaseUK congenital heart information and family care context.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom